Forbion – Talk Bio

Gate Bioscience Captures $65M Series B to Advance Molecular Gate Protein Degradation Platform

4 weeks ago talkbio0Tagged Bio + Health, eli lilly, Forbion, Gate Bioscience, innovation, Molecular Gates, Precision Medicine, Protein Degradation, Metabolic, protein elimination therapeutics, Series B funding

Gate Bioscience; protein degradation; protein elimination therapeutics; Series B funding; Molecular Gates; Eli Lilly; Forbion; a16z Bio + Health; precision medicine; biotech innovation

Braveheart Bio Launches with $185 Million Series A, Appoints Biogen CEO Christopher Viehbacher as Chair

1 month ago talkbio0Tagged Andreessen Horowitz, BHB-1893, Biogen CEO, Braveheart Bio, Christopher Viehbacher, Forbion, Hypertrophic Cardiomyopathy, myosin inhibitor, OrbiMed, Series A financing

Braveheart Bio; Series A financing; hypertrophic cardiomyopathy; Christopher Viehbacher; Biogen CEO; cardiovascular drug development; BHB-1893; myosin inhibitor; Andreessen Horowitz; Forbion; OrbiMed

Elevara Raises $70M to Advance Novel Rheumatoid Arthritis Treatment Targeting Synovial Fibroblasts

2 months ago talkbio0Tagged CDK4/6 inhibitor, Chronic inflammatory disorder, Clinical Trials, Elevara Medicines, ELV001, Forbion, Partner in relationship, Pharma, Rheumatoid Arthritis, Series A financing, Sofinnova, synovial fibroblasts, Teijin

Elevara Medicines; Series A financing; rheumatoid arthritis; ELV001; CDK4/6 inhibitor; synovial fibroblasts; Teijin Pharma; clinical trial; chronic inflammatory diseases; Forbion; Sofinnova Partners

Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study

3 months ago talkbio0Tagged Capital Management, clofutriben, Diabetes Mellitus, Non-Insulin-Dependent, Forbion, hydrocortisone, Psychological inhibition, Rheumatoid Arthritis, Series B fundraising, SPAG8 gene, Sparrow Pharmaceuticals, venture

Sparrow Pharmaceuticals; Series B fundraising; Type 2 diabetes; clofutriben; phase 2b trial; HSD-1 inhibition; cortisol; RA Capital Management; Forbion; venture capital

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

7 months ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy

1 year ago talkbio0Tagged Citryll, Forbion, Inflammatory Disease Therapy, Johnson & Johnson Innovation, Neutrophil Extracellular Traps, Novartis, Series B, venture fund

Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion